12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Diazepam nasal spray regulatory update

Acorda said it submitted an NDA to FDA for its diazepam nasal spray to treat acute repetitive seizures in epileptics. The company submitted the product under section 505(b)(2)...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >